Biocon Limited operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biocon Limited with three other
pharmaceutical manufacturers in Asia:
Celltrion HealthCare Co Ltd
of South Korea
sales of 713.49 billion Korean Won [US$630.01 million]
of which 96%
was Goods Sales),
Yifan Pharmaceutical Co Ltd
(4.63 billion Chinese Renmimbi [US$692.55 million]
of which 66%
was Health Products - Medicine), and
Hualan Biological Engineering Inc
based in China
(3.22 billion Chinese Renmimbi [US$480.99 million]
of which 75%
was Blood Product).
Biocon Limited reported sales of 41.23 billion Indian Rupees (US$593.77 million)
March of 2018.
increase of 6.0%
versus 2017, when the company's sales were 38.91 billion Indian Rupees.
Sales at Biocon Limited have increased during each of the previous five years
(and since 2013, sales have increased a total of 68%).
Sales of Research Services saw an increase
that was more than double the company's growth rate: sales were up
19.3% in 2018, from
11.93 billion Indian Rupees to 14.23 billion Indian Rupees.
Biocon Limited also saw significant increases in sales in
Biologics (up 9.7% to 7.70 billion Indian Rupees)
Branded Formulation (up 11.4% to 6.12 billion Indian Rupees)
Not all segments of Biocon Limited experienced an increase in sales in 2018:
sales of Small Molecules fell 8.1% to 15.08 billion Indian Rupees.